title: Stent thrombosis up to 3 years after stenting for ST-segment elevation myocardial infarction versus for stable angina--comparison of the effects of drug-eluting versus bare-metal stents.
abstract: BACKGROUND
  The long-term safety of drug-eluting stents (DES) for the treatment of ST-segment elevation myocardial infarction (STEMI) is unclear and may differ from that in stable angina (stable) patients as noted in autopsy studies.
  
  
  METHODS
  To assess this problem, 210 consecutive STEMI and 323 stable patients, randomized 2:1 to DES versus bare-metal stents (BMS), were followed up for 3 years for definite/probable stent thrombosis (ST) and cardiac death/myocardial infarction. Events occurring during the initial 6 months were separated from later events.
  
  
  RESULTS
  The 3-year rate of ST was 8.1% in STEMI vs 3.4% in stable patients (P = .02), with corresponding rates of 9.4% vs 2.9% (P = .01) for DES and of 5.6% vs 4.3% (P = .71) for BMS patients, respectively. This difference appeared only after 6 months: 4.6% in STEMI vs 1.7% in stable patients (P = .05) and in DES-treated patients (6.2% vs 2.0%, P = .05). Results of ST were paralleled by findings of clinical events, although here differences were less pronounced, but also seen only late after stenting. Thus, in STEMI patients, late events occurred more frequently after DES vs BMS implantation (11.6% vs 3.0%, P = .04), compared to results in stable patients (DES 6.4%, BMS 1.9%, P = .08).
  
  
  CONCLUSIONS
  In this pilot study, we observed an increased rate of late ST and a trend to more related clinical events in patients after stenting for STEMI vs for stable angina, particularly if treated with DES. This may explain outcome differences between results of pivotal trials in stable patients vs those of "real-world" patients.
authors.affiliation: Department of Cardiology, University Hospital Basel CH-4031, Switzerland.
authors.forename: Gregor
authors.initials: G
authors.lastname: Leibundgut
authors.forename: Fabian
authors.initials: F
authors.lastname: Nietlispach
authors.forename: Undine
authors.initials: U
authors.lastname: Pittl
authors.forename: Hanspeter
authors.initials: H
authors.lastname: Brunner-La Rocca
authors.forename: Christoph A
authors.initials: CA
authors.lastname: Kaiser
authors.forename: Matthias E
authors.initials: ME
authors.lastname: Pfisterer
mesh_terms: D000787:Angina Pectoris / Q000628:therapy*; D000077144:Clopidogrel; D054855:Drug-Eluting Stents / Q000009:adverse effects; D023381:Endpoint Determination; D006801:Humans; D009203:Myocardial Infarction / Q000628:therapy*; D010865:Pilot Projects; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D015607:Stents / Q000009:adverse effects; D013927:Thrombosis / Q000453:epidemiology*; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine